Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of “Hold” by Analysts

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) have received a consensus rating of “Hold” from the five research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $4.50.

A number of research analysts have commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, January 22nd. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Heron Therapeutics in a research note on Friday, January 9th.

Heron Therapeutics Price Performance

HRTX stock opened at $0.80 on Friday. The firm’s 50-day moving average price is $1.08 and its two-hundred day moving average price is $1.20. Heron Therapeutics has a 12-month low of $0.74 and a 12-month high of $2.61. The stock has a market capitalization of $150.68 million, a price-to-earnings ratio of -6.15 and a beta of 1.42. The company has a current ratio of 2.48, a quick ratio of 1.51 and a debt-to-equity ratio of 10.59.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $40.59 million for the quarter, compared to analysts’ expectations of $39.53 million. As a group, equities analysts predict that Heron Therapeutics will post -0.13 earnings per share for the current year.

Institutional Investors Weigh In On Heron Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Redwood Family Wealth LLC purchased a new position in shares of Heron Therapeutics during the fourth quarter valued at about $84,000. Caitong International Asset Management Co. Ltd lifted its holdings in Heron Therapeutics by 335.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 35,106 shares of the biotechnology company’s stock worth $46,000 after buying an additional 27,040 shares during the period. Invesco Ltd. boosted its position in Heron Therapeutics by 33.0% during the 4th quarter. Invesco Ltd. now owns 307,861 shares of the biotechnology company’s stock valued at $400,000 after acquiring an additional 76,466 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Heron Therapeutics by 687.6% during the 4th quarter. XTX Topco Ltd now owns 240,197 shares of the biotechnology company’s stock worth $312,000 after acquiring an additional 209,700 shares during the period. Finally, Tang Capital Management LLC grew its holdings in shares of Heron Therapeutics by 81.2% during the 4th quarter. Tang Capital Management LLC now owns 6,250,000 shares of the biotechnology company’s stock worth $8,125,000 after acquiring an additional 2,800,000 shares during the period. 80.01% of the stock is owned by hedge funds and other institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.